Emcure Pharmaceuticals Ltd (EMCURE) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 10039308,
    "name": "Emcure Pharma",
    "stock_name": "Emcure Pharma",
    "full_name": "Emcure Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/emcure-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,744.20",
    "chg": 20.8,
    "chgp": "1.21%",
    "dir": 1,
    "prev_price": "1,723.40",
    "mcapval": "33,080.42 Cr",
    "mcap": "Small Cap",
    "scripcode": 544210,
    "symbol": "EMCURE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE168P01015",
    "curr_date": "Jun 18",
    "curr_time": "",
    "bse_nse_vol": "56.14 k",
    "exc_status": "Active",
    "traded_date": "Jun 18, 2026",
    "traded_date_str": "2026 06 18",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://marketsmojo.motilaloswal.com/MOSL-Landingstocks-analysis/emcure-pharma-10039308-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Emcure Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-4000693",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_mojoScore_4000693.png",
        "date": "2026-05-20 10:10:56",
        "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Valuation Shifts Signal Caution Amid Strong Returns",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-valuation-shifts-signal-caution-amid-strong-returns-3997949",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_valuationdot_3997949.png",
        "date": "2026-05-19 08:03:05",
        "description": "Emcure Pharmaceuticals Ltd has experienced a notable change in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, prompting a reassessment of its price attractiveness amid sector peers and historical benchmarks. Despite strong operational metrics, the stock’s elevated price-to-earnings and price-to-book ratios suggest a cautious stance for investors evaluating entry or exit points."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd is Rated Hold",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-ltd-is-rated-hold-3982715",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_mojoScore_3982715.png",
        "date": "2026-05-09 10:10:36",
        "description": "Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its performance and prospects."
      },
      {
        "title": "Emcure Pharmaceuticals Drops 8.04%: 5 Key Factors Behind This Week’s Decline",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-drops-804-5-key-factors-behind-this-weeks-decline-3982653",
        "imagepath": "",
        "date": "2026-05-09 10:01:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>4 May:</strong> New 52-week and all-time high at Rs.1,805 (intraday)</p>\n                    <p><strong>5 May:</strong> Stock hits another 52-week high at Rs.1,830.35</p>\n                    <p><strong>5 May:</strong> Q4 FY26 results reveal strong topline but margin pressures</p>\n                    <p><strong>6 May:</strong> Flat quarterly performance reported amid rising interest costs</p>\n                    <p><strong>8 May:</strong> Week closes at Rs.1,641.60, down 8.04%</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,785.15</div></div>\n          ..."
      },
      {
        "title": "Are Emcure Pharmaceuticals Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-emcure-pharmaceuticals-ltd-latest-results-good-or-bad-3978414",
        "imagepath": "",
        "date": "2026-05-06 19:19:53",
        "description": "Emcure Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported consolidated net sales of ₹2,469.70 crores, reflecting a year-on-year growth of 16.70% and a sequential increase of 4.49% from the previous quarter. This growth indicates Emcure's ability to capture market share and maintain revenue momentum in a competitive pharmaceutical landscape.\n\nOn the profitability front, the consolidated net profit reached ₹243.40 crores, marking a significant year-on-year increase of 28.81%. However, the operating margin, which stood at 19.42%, experienced a contraction of 143 basis points from the previous quarter, highlighting challenges related to rising input costs and competitive pricing pressures. The profit after tax margin improved slightly to 9.87% compared to the previous year, yet the overall margin dynamics suggest a need for careful..."
      },
      {
        "title": "Emcure Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-reports-flat-quarterly-performance-amid-margin-pressures-3976687",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_fintrenddot_3976687.png",
        "date": "2026-05-06 08:00:15",
        "description": "Emcure Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving record net sales and robust profit after tax growth over the last six months, rising interest expenses and margin pressures have tempered investor enthusiasm, reflected in a recent downgrade of its Mojo Grade from Buy to Hold."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1830.35",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-hits-new-52-week-high-at-rs183035-3975497",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_priceRelatedfactors_3975497.png",
        "date": "2026-05-05 09:49:32",
        "description": "Surging past its previous peaks, Emcure Pharmaceuticals Ltd touched a new 52-week high of Rs 1830.35 on 5 May 2026, marking a remarkable 77.88% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price action, even as the broader market struggles to maintain its footing."
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1825.5 as Momentum Builds Across Timeframes",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-hits-all-time-high-at-rs18255-on-5-may-2026-3975432",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_priceRelatedfactors_3975432.png",
        "date": "2026-05-05 09:34:57",
        "description": ""
      },
      {
        "title": "Emcure Pharmaceuticals Ltd Valuation Shifts Signal Heightened Price Attractiveness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-ltd-valuation-shifts-signal-heightened-price-attractiveness-3974702",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/EmcurePharmaceu_valuationdot_3974702.png",
        "date": "2026-05-05 08:01:42",
        "description": "Emcure Pharmaceuticals Ltd has witnessed a significant re-rating in its valuation metrics, transitioning from an expensive to a very expensive stock within the Pharmaceuticals & Biotechnology sector. This shift accompanies a robust price rally, with the stock surging over 6% in a single trading session and outperforming benchmark indices substantially over multiple time horizons."
      }
    ],
    "total": 15,
    "sid": "10039308",
    "stock_news_url": "https://marketsmojo.motilaloswal.com/news/emcure-pharmaceuticals-10039308"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
      "datetime": "12-Jun-2026",
      "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Investor Presentation - June 2026",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Reg.24(A)-Annual Secretarial Compliance",
      "datetime": "27-May-2026",
      "details": "Annual Secretarial Compliance Report for the Financial Year ended March 31 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "20-May-2026",
      "details": "Intimation of schedule of Analyst/ Investor Meeting on June 01 2026",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Emcure Pharmaceuticals Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Emcure Pharmaceuticals Ltd is Rated Hold

2026-05-20 10:10:56

Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 20 May 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Emcure Pharmaceuticals Ltd Valuation Shifts Signal Caution Amid Strong Returns

2026-05-19 08:03:05

Emcure Pharmaceuticals Ltd has experienced a notable change in its valuation parameters, moving from a 'very expensive' to an 'expensive' rating, prompting a reassessment of its price attractiveness amid sector peers and historical benchmarks. Despite strong operational metrics, the stock’s elevated price-to-earnings and price-to-book ratios suggest a cautious stance for investors evaluating entry or exit points.

Emcure Pharmaceuticals Ltd is Rated Hold

2026-05-09 10:10:36

Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 May 2026, providing investors with an up-to-date view of its performance and prospects.

Emcure Pharmaceuticals Drops 8.04%: 5 Key Factors Behind This Week’s Decline

2026-05-09 10:01:59

Key Events This Week 4 May: New 52-week and all-time high at Rs.1,805 (intraday) 5 May: Stock hits another 52-week high at Rs.1,830.35 5 May: Q4 FY26 results reveal strong topline but margin pressures 6 May: Flat quarterly performance reported amid rising interest costs 8 May: Week closes at Rs.1,641.60, down 8.04% Week OpenRs.1,785.15 ...

Are Emcure Pharmaceuticals Ltd latest results good or bad?

2026-05-06 19:19:53

Emcure Pharmaceuticals Ltd's latest financial results for Q4 FY26 present a mixed picture of operational performance. The company reported consolidated net sales of ₹2,469.70 crores, reflecting a year-on-year growth of 16.70% and a sequential increase of 4.49% from the previous quarter. This growth indicates Emcure's ability to capture market share and maintain revenue momentum in a competitive pharmaceutical landscape. On the profitability front, the consolidated net profit reached ₹243.40 crores, marking a significant year-on-year increase of 28.81%. However, the operating margin, which stood at 19.42%, experienced a contraction of 143 basis points from the previous quarter, highlighting challenges related to rising input costs and competitive pricing pressures. The profit after tax margin improved slightly to 9.87% compared to the previous year, yet the overall margin dynamics suggest a need for careful...

Emcure Pharmaceuticals Reports Flat Quarterly Performance Amid Margin Pressures

2026-05-06 08:00:15

Emcure Pharmaceuticals Ltd has reported a flat financial performance for the quarter ended March 2026, marking a significant shift from its previously positive growth trajectory. Despite achieving record net sales and robust profit after tax growth over the last six months, rising interest expenses and margin pressures have tempered investor enthusiasm, reflected in a recent downgrade of its Mojo Grade from Buy to Hold.

Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1830.35

2026-05-05 09:49:32

Surging past its previous peaks, Emcure Pharmaceuticals Ltd touched a new 52-week high of Rs 1830.35 on 5 May 2026, marking a remarkable 77.88% gain over the past year. This milestone comes amid a backdrop of strong technical momentum and sustained upward price action, even as the broader market struggles to maintain its footing.

Emcure Pharmaceuticals Ltd Hits All-Time High of Rs 1825.5 as Momentum Builds Across Timeframes

2026-05-05 09:34:57

Emcure Pharmaceuticals Ltd Valuation Shifts Signal Heightened Price Attractiveness

2026-05-05 08:01:42

Emcure Pharmaceuticals Ltd has witnessed a significant re-rating in its valuation metrics, transitioning from an expensive to a very expensive stock within the Pharmaceuticals & Biotechnology sector. This shift accompanies a robust price rally, with the stock surging over 6% in a single trading session and outperforming benchmark indices substantially over multiple time horizons.

View All News